InvestorsHub Logo
Followers 5
Posts 62
Boards Moderated 0
Alias Born 12/04/2013

Re: lasers post# 183560

Thursday, 02/11/2016 11:03:03 AM

Thursday, February 11, 2016 11:03:03 AM

Post# of 403471
lasers - I was a little confused on this one. It sounds like NH is NOT going to pursue ELI 202 because according to the FDA the nal and the apap are redundant. Here's what NH said:

Therefore adding Naltrexone which is an expensive substance and it costs another $15 million, clinical trial does not give us any edge over just using APAP


So do you think Elite is going forward with ELI 202?

thnx as always for your insight.

rib
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News